You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Case report
Off-label application of intravenous immunoglobulin (IVIG) for treatment of Cogan’s syndrome during pregnancy
  1. Felix Scherg1,
  2. Friedrich Haag1 and
  3. Thorsten Krieger2,3
  1. 1 Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  2. 2 Institute of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  3. 3 Department of Primary Immunodeficiencies, MVZ Rheumatologie und Autoimmunmedizin GmbH, Hamburg, Germany
  1. Correspondence to Dr Thorsten Krieger, krieger{at}uke.de, t.krieger{at}rheuma-hh.de

Abstract

We report the case of a woman with Cogan’s syndrome concomitant with the wish to have children. After three major flares of the disease that led to unilateral deafness, immunosuppressive therapy with prednisolone and azathioprine was started. Because of the severe side effects, an off-label therapy with intravenous immunoglobulin (IVIG) was initiated, under which our patient has since given birth to three healthy children. To our knowledge this is the first report to describe Cogan’s syndrome with multiple successful pregnancies under IVIG treatment.

  • immunology
  • pregnancy
  • ear, nose And throat

https://doi.org/10.1136/bcr-2018-227917

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors FS: drafting the manuscript, acquisition of data, patient consent. FH: drafting the manuscript, revising the manuscript. TK: treating the patient, acquisition of data, revising the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Obtained.